Laboratory Medicine ›› 2022, Vol. 37 ›› Issue (12): 1178-1182.DOI: 10.3969/j.issn.1673-8640.2022.12.015
Previous Articles Next Articles
Received:2021-02-22
Revised:2022-02-10
Online:2022-12-30
Published:2023-02-02
CLC Number:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2022.12.015
| 样本编号 | 理论值/（IU/L） | 实测值的x/（IU/L） | 线性拟合值/（IU/L） | 多项式拟合值/（IU/L） | CV/% | 线性拟合偏差/% |
|---|---|---|---|---|---|---|
| TSI | ||||||
| 1 | 0.27 | 0.27 | 1.66 | 0.16 | 21.7 | -89.8 |
| 2 | 9.82 | 11.83 | 11.23 | 11.95 | 5.2 | 6.4 |
| 3 | 19.37 | 22.03 | 20.85 | 22.30 | 1.5 | 6.9 |
| 4 | 28.92 | 31.67 | 30.48 | 31.20 | 1.2 | 2.4 |
| 5 | 38.47 | 38.47 | 40.10 | 38.66 | 0.9 | -3.6 |
| TRAb | ||||||
| 1 | 1.00 | 1.00 | 3.00 | 0.95 | 10.0 | -68.9 |
| 2 | 10.50 | 13.20 | 12.70 | 13.40 | 1.6 | 5.7 |
| 3 | 20.00 | 24.90 | 22.30 | 24.60 | 1.2 | 10.4 |
| 4 | 29.40 | 33.20 | 31.80 | 33.40 | 0.3 | 5.1 |
| 5 | 38.90 | 38.90 | 41.40 | 38.90 | 0.1 | -6.2 |
| 样本编号 | 理论值/（IU/L） | 实测值的x/（IU/L） | 线性拟合值/（IU/L） | 多项式拟合值/（IU/L） | CV/% | 线性拟合偏差/% |
|---|---|---|---|---|---|---|
| TSI | ||||||
| 1 | 0.27 | 0.27 | 1.66 | 0.16 | 21.7 | -89.8 |
| 2 | 9.82 | 11.83 | 11.23 | 11.95 | 5.2 | 6.4 |
| 3 | 19.37 | 22.03 | 20.85 | 22.30 | 1.5 | 6.9 |
| 4 | 28.92 | 31.67 | 30.48 | 31.20 | 1.2 | 2.4 |
| 5 | 38.47 | 38.47 | 40.10 | 38.66 | 0.9 | -3.6 |
| TRAb | ||||||
| 1 | 1.00 | 1.00 | 3.00 | 0.95 | 10.0 | -68.9 |
| 2 | 10.50 | 13.20 | 12.70 | 13.40 | 1.6 | 5.7 |
| 3 | 20.00 | 24.90 | 22.30 | 24.60 | 1.2 | 10.4 |
| 4 | 29.40 | 33.20 | 31.80 | 33.40 | 0.3 | 5.1 |
| 5 | 38.90 | 38.90 | 41.40 | 38.90 | 0.1 | -6.2 |
| TRAb | TSI | |
|---|---|---|
| 阴性 | 阳性 | |
| 阴性 | 275（53.0） | 28（5.4） |
| 阳性 | 16（3.1） | 200（38.5） |
| TRAb | TSI | |
|---|---|---|
| 阴性 | 阳性 | |
| 阴性 | 275（53.0） | 28（5.4） |
| 阳性 | 16（3.1） | 200（38.5） |
| 1 |
MORSHED S A, DAVIES T F. Graves' disease mechanisms:the role of stimulating,blocking,and cleavage region TSH receptor antibodies[J]. Horm Metab Res, 2015, 47(10):727-734.
DOI URL |
| 2 |
SOH S B, AW T C. Laboratory testing in thyroid conditions-pitfalls and clinical utility[J]. Ann Lab Med, 2019, 39(1):3-14.
DOI URL |
| 3 |
MORSHED S A, LATIF R, DAVIES T F. Characterization of thyrotropin receptor antibody-induced signaling cascades[J]. Endocrinology, 2009, 150(1):519-529.
DOI PMID |
| 4 | LUTTRELL B M, HALES I B. Thyroid stimulating immunoglobulin in Graves' disease[J]. Aust N Z J Med, 1981, 11(3):293-298. |
| 5 |
VILLALTA D, ORUNESU E, TOZZOLI R, et al. Analytical and diagnostic accuracy of "second generation" assays for thyrotrophin receptor antibodies with radioactive and chemiluminescent tracers[J]. J Clin Pathol, 2004, 57(4):378-382.
DOI PMID |
| 6 |
TOZZOLI R, D'AURIZIO F, VILLALTA D, et al. Evaluation of the first fully automated immunoassay method for the measurement of stimulating TSH receptor autoantibodies in Graves' disease[J]. Clin Chem Lab Med, 2017, 55(1):58-64.
DOI URL |
| 7 | Clinical and Laboratory Standards Institute. User verification of precision and estimation of bias[S]. EP15-A3,CLSI, 2014. |
| 8 | Clinical and Laboratory Standards Institute. Evaluation of the linearity of quantitative measurement procedures:a statistical approach[S]. EP06-A,CLSI, 2003. |
| 9 | Clinical and Laboratory Standards Institute. Method comparison and bias estimation using patient samples[S]. EP9-A2,CLSI, 2002. |
| 10 | Clinical and Laboratory Standards Institute. User protocol for evaluation of qualitative test performance[S]. EP12-A2,CLSI, 2008. |
| 11 |
LANDIS J R, KOCH G G. The measurement of observer agreement for categorical data[J]. Biometrics, 1977, 33(1):159-174.
PMID |
| 12 |
ROSS D S, BURCH H B, COOPER D S, et al. 2016 American thyroid association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis[J]. Thyroid,2016, 26(10):1343-1421.
DOI URL |
| 13 |
YAMASHITA S, AMINO N, SHONG Y K. The American thyroid association and american association of clinical endocrinologists hyperthyroidism and other causes of thyrotoxicosis guidelines:viewpoints from Japan and Korea[J]. Thyroid, 2011, 21(6):577-580.
DOI URL |
| 14 |
KIM J J, JEONG S H, KIM B, et al. Analytical and clinical performance of newly developed immunoassay for detecting thyroid-stimulating immunoglobulin,the Immulite TSI assay[J]. Scand J Clin Lab Invest, 2019, 79(6):443-448.
DOI URL |
| 15 |
AUTILIO C, MORELLI R, LOCANTORE P, et al. Stimulating TSH receptor autoantibodies immunoassay:analytical evaluation and clinical performance in Graves' disease[J]. Ann Clin Biochem, 2018, 55(1):172-177.
DOI URL |
| 16 | BLUSZCZ G A, BEDNARCZUK T, BARTOSZEWICZ Z, et al. Clinical utility of TSH receptor antibody levels in Graves' orbitopathy:a comparison of two TSH receptor antibody immunoassays[J]. Cent Eur J Immunol, 2018, 43(4):405-412. |
| 17 |
ALLELEIN S, EHLERS M, GORETZKI S, et al. Clinical evaluation of the first automated assay for the detection of stimulating TSH receptor autoantibodies[J]. Horm Metab Res, 2016, 48(12):795-801.
PMID |
| 18 |
CHENG X, CHAI X, MA C, et al. Clinical diagnostic performance of a fully automated TSI immunoassay vs. that of an automated antiTSHR immunoassay for Graves' disease:a Chinese multicenter study[J]. Endocrine, 2021, 71(1):139-148.
DOI URL |
| 19 | 张利霞, 汪蕾, 郭琳, 等. 促甲状腺素受体刺激性抗体检测的临床意义[J]. 标记免疫分析与临床, 2019, 26(12):1985-1987. |
| 20 | 钟丽, 张静, 张双婕, 等. IMMULITE化学发光TSI检测分析性能验证及临床性能评估[J]. 标记免疫分析与临床, 2021, 28(2):339-342. |
| 21 | 刘天琪, 张秀英, 纪立农. 促甲状腺激素受体抗体的检测及应用进展[J]. 国际内分泌代谢杂志, 2021, 41(1):5-9. |
| [1] | FAN Lieying. Research status and application prospects of biomarkers for membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1111-1114. |
| [2] | SUN Lincheng, LI Jianfeng, CHENG Weili, JI Panyun. Roles of anti-PLA2R IgG4 antibody and PLA2R IgG4/IgG ratio in primary membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1115-1120. |
| [3] | LIU Qingyang, YUAN Jianming, XIA Jinjun, JIANG Fengying, WANG Qiubo, WANG Xiaoming. CXCL9 as a potential diagnostic marker of rheumatoid arthritis based on GEO database and experimental verification [J]. Laboratory Medicine, 2023, 38(12): 1121-1129. |
| [4] | YANG Xiao, LI Enling, WU Lixia, DAI Yingxin, WANG Zhiqing, HUANG Hao, ZHENG Bing. Influence of cytoplasmic antinuclear antibody on indirect immunofluorescence assay based antineutrophil cytoplasmic antibody determination [J]. Laboratory Medicine, 2023, 38(12): 1135-1140. |
| [5] | XIANG Jin, LIU Aiping, HU Yao, WU Zhiyuan, CAO Guojun, GUAN Ming. ANA profiles in COVID-19 patients and influence of serum heat-inactivation on ANA determination [J]. Laboratory Medicine, 2023, 38(12): 1141-1146. |
| [6] | CHENG Yu, XU Zhen, LU Liu, DING Menglei, YU Shanshan, ZONG Ming, FAN Lieying. Expression and risk factors of anti-ACE-2 antibody in serum of patients with COVID-19 [J]. Laboratory Medicine, 2023, 38(12): 1147-1152. |
| [7] | . [J]. Laboratory Medicine, 2023, 38(12): 1153-1156. |
| [8] | . [J]. Laboratory Medicine, 2023, 38(12): 1157-1159. |
| [9] | WANG Hongling, LIU Mengna, BAI Ping, LIAO Huanjin. Risk factors of relapse following allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia [J]. Laboratory Medicine, 2023, 38(12): 1160-1166. |
| [10] | YANG Xilan, WANG Jinyu, LIU Shuyu, ZHAN Yiyang, LIU Jing, JIA Jian. Correlation between hyperlipidemia and endothelial microparticles in elderly patients from Gulou Community in Nanjing [J]. Laboratory Medicine, 2023, 38(12): 1167-1172. |
| [11] | DAI Fangfang, LU Xinxin, YU Yanhua, CHEN Ming, SUN Guizhen. Analysis of Mycobacterium infection in HIV/AIDS patients [J]. Laboratory Medicine, 2023, 38(12): 1173-1176. |
| [12] | GU Yu, LIANG Xiaoyan, MA Shenghui, TONG Na, CHENG Mingyan, YAN Zejun. Expression and near-term prognostic predictive value of plasma biomarkers in chronic kidney disease patients with thromboembolism [J]. Laboratory Medicine, 2023, 38(12): 1177-1182. |
| [13] | . [J]. Laboratory Medicine, 2023, 38(12): 1183-1185. |
| [14] | . [J]. Laboratory Medicine, 2023, 38(12): 1186-1190. |
| [15] | . [J]. Laboratory Medicine, 2023, 38(12): 1191-1194. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
